Chronic vasodilator therapy with flosequinan in <font color="red">congestive_2</font> <font color="red">heart_2</font> <font color="red">failure_2</font> <font color="red">._2</font> 
<br>
<br> This study was conducted to determine the long - term effect of flosequinan , a new orally administered arterial and venous dilator , on the clinical course of <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">moderate_2</font> <font color="red">to_2</font> <font color="red">severe_2</font> <font color="red">congestive_2</font> <font color="red">heart_2</font> <font color="red">failure_2</font> <font color="red">._2</font> <font color="red">Seventeen_2</font> <font color="red">patients_2</font> <font color="red">on_2</font> <font color="red">chronic_2</font> <font color="red">digitalis_2</font> <font color="red">and_2</font> <font color="red">diuretic_2</font> <font color="red">therapy_2</font> were randomized to receive either flosequinan ( n = 9 ) or placebo ( n = 8) in a double - blind fashion . Changes in symptomatology , exercise performance , and left ventricular function were assessed serially during the two - month treatment period . During the course of therapy , a modest improvement in the symptom scores and functional classification of the flosequinan - treated patients was observed . Flosequinan evoked a significant increase in maximal exercise capacity . While long - term flosequinan administration also effected a progressive increase in resting heart rate , it did not consistently improve indices of left ventricular systolic function . The addition of chronic vasodilator therapy with flosequinan to standard digitalis - diuretic regimens is capable of inducing clinical improvement in <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">moderate_2</font> <font color="red">to_2</font> <font color="red">severe_2</font> <font color="red">chronic_2</font> <font color="red">heart_2</font> <font color="red">failure_2</font> <font color="red">._2</font> Trials involving larger patient populations will be necessary to confirm the results of this preliminary study and to determine the extent of clinical improvement , subpopulations benefited , role in <font color="red">heart_1</font> <font color="red">failure_1</font> therapeutics , and so forth .